Humanin vs Epitalon: What Differs

Humanin and Epitalon show up together in longevity-peptide forums, but they differ in almost everything that matters: origin, molecular size, and the research line that studies each one. Humanin is a 24-amino-acid peptide encoded in the mitochondrial genome, studied in the literature for a cytoprotective, antiapoptotic role. Epitalon is a synthetic tetrapeptide of just 4 amino acids, derived from a natural pineal gland peptide, studied for its relationship to telomerase and circadian rhythms. They share no structure and no mechanism — the only real overlap is that popular culture files them under the same "longevity peptide" label.

That difference in origin and size is what explains everything else: how each one is produced, how stable it is, and what kind of assay is used to study it.

Where each peptide comes from

Humanin was not designed — it was discovered. In 2001, a research group identified a sequence inside the mitochondrial gene MT-RNR2 — the region that encodes part of the 16S ribosomal RNA — that translates into a 24-amino-acid peptide. This is what is now known as a mitochondrial-derived peptide (MDP): a small family of molecules the mitochondrial genome produces in addition to the respiratory-chain proteins. Humanin was the first MDP described.

Epitalon, by contrast, is synthetic from the start. It is based on a natural peptide extracted from the pineal gland called epithalamin, and it was reduced by Vladimir Khavinson's laboratory (Saint Petersburg Institute of Bioregulation and Gerontology) to its minimal active sequence: alanine-glutamic acid-aspartic acid-glycine (Ala-Glu-Asp-Gly). That synthesis dates to the 1980s and 1990s, with the stated goal of replicating in the lab what natural epithalamin did in animal models.

The /en/product/epitalon/ page has the technical specification for Epitalon as a research material, including the purity spec and what documentation ships with a lot. Humanin is not part of PeptoClinic's catalogue.

What the literature investigates about humanin

Most published work on humanin concentrates on its ability to protect cells against toxic stimuli — a mechanism referred to as cytoprotection. The earliest studies identified it in neurons resistant to effects associated with Alzheimer's disease, and from there the research expanded into models of apoptosis, mitochondrial oxidative stress, and metabolic regulation.

Humanin does not stand alone in its category: it belongs to the family of mitochondrial-derived peptides, alongside MOTS-c, which is encoded in a different region of mitochondrial DNA (the 12S rRNA gene) and is studied mainly in the context of energy metabolism and insulin sensitivity in animal models. Comparing humanin to MOTS-c makes more biological sense than comparing it to Epitalon: the first two share mitochondrial origin, even though the mechanisms under study differ.

The published work on humanin and its discovery can be reviewed on PubMed, where the original 2001 identification and the subsequent neurodegeneration research are documented.

What the literature investigates about Epitalon

Epitalon is studied in a different area: the relationship between the pineal gland, circadian rhythm, and cellular aging. The most cited finding from Khavinson's group is telomerase activation in cultured human fibroblasts, published in the early 2000s, which opened a line of study on telomere maintenance in in vitro models.

Other work from the same team investigated Epitalon in animal models of retinal aging and in the regulation of melatonin secretion, always within the frame of biological-clock research. It is a consistent, Russia-based research line, with decades of publications from the same laboratory — unlike humanin, which was taken up by multiple independent research groups in different countries after its discovery.

The literature on telomerase and Epitalon is also indexed on PubMed, useful for reading the original studies rather than a secondhand summary.

Size and stability: the most concrete difference

Beyond mechanism, there is a structural difference anyone can check just by looking at a spec sheet: humanin has 24 amino acids, Epitalon has 4. A long-chain peptide like humanin has more possible points of degradation — more peptide bonds to break, more surface exposed to oxidation — than a tetrapeptide does. That says nothing about biological efficacy, but it says a lot about how demanding the cold chain and batch handling are as a laboratory material.

On a certificate of analysis, a short peptide like Epitalon usually shows a cleaner, easier-to-read HPLC peak than a long-chain one, simply because there are fewer possible incomplete-sequence variants. The /en/quality/ page explains how to read a Janoshik Analytical certificate of analysis and what to check before accepting a lot's stated purity.

Why they get searched together

The search "humanin o epithalon en qué se diferencian" almost always comes from the same curiosity: someone read about longevity research, saw both names on the same list, and wants to know if they're interchangeable. They are not — not in structure, and not in the research question each one answers. PeptoClinic supplies research peptides to Argentina as laboratory reference material, with import documentation prepared for that category, and the full catalogue is listed at /en/catalog/.

The reverse point also holds: high search interest in a compound does not mean it is available. Humanin is not in the current catalogue, and this note is not a promise that it will be added.

Laboratory material, not for human or veterinary use

Both humanin and Epitalon, when available, are supplied strictly as research material (Research Use Only): for laboratory and in vitro study. Neither is a medicine, a supplement, or a product for human or veterinary consumption, and none of their properties has been evaluated by the FDA, ANMAT, or an equivalent authority. This article describes what published scientific literature investigates — it is not usage guidance or a protocol.